Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Qnexa Facing Uphill Battle Over Safety

By Drug Discovery Trends Editor | July 13, 2010

NEW YORK (AP) – Vivus Inc.’s potential weight loss drug Qnexa will likely draw scrutiny over nervous system and psychiatric side effects from a panel of Food and Drug Administration experts this week.

The FDA acknowledges the potential blockbuster drug’s effectiveness in cutting weight. But, in briefing documents posted online Tuesday the agency raised concerns about a range of side effects. It said reviewers should take into account rates of depression, memory and concentration lapses, and heart-related issues, among others.

A panel of experts is scheduled to review the drug on Thursday, with the FDA making a regulatory decision in October.

“Given two-thirds of adults in the United States are either overweight or obese, weight loss products, such as Qnexa, may have widespread exposure, and the potential for associated safety issues must be considered,” the agency said.

Qnexa is the first of several new weight loss drugs to come under FDA review and Wall Street has been following its progress through human studies to gauge its potential.

The drug met key goals in several studies, cutting between 13 percent and 15 percent of patients’ body weight. But the FDA is concerned about five types of side effects, including heart risks, increased risk of suicide, metabolic issues, and the potential impact on pregnant women.

Vivus, in its own briefing documents, said research showing that 68 percent of adults in the U.S. are overweight indicate a clear medical need for Qnexa.

“Recent data suggest that if current increases in obesity rates continue over the next decade, the health consequences of obesity will negate the gains in health benefits achieved through the reduction in smoking rates,” Vivus said.

In premarket trading, shares of the Mountain View, Calif., company soared 32 percent to $14.10. The stock has rallied 80 percent in the past year.

The obesity problem in America underscores the financial potential of any new weight loss drug. But the search for a new drug has faced decades worth of safety issues. A key example includes fen-phen, which was pulled off the market in 1997 because of links to heart-valve damage and lung problems.

Aside from Qnexa, the FDA is set to review Arena Pharmaceuticals Inc.’s lorcaserin in September, while Orexigen Therapeutics Inc.’s Contrave will be the subject of a December panel.

Date: July 13, 2010
Source: Associated Press

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE